The Spanish biotechnology and medicine company PlusVitech has launched a Phase II clinical trial to treat patients with incurable lung cancer with the treatments available to date.
The PVT-REMOVE treatment that PlusVitech proposes in this clinical trial, repositioning an oral drug that, according to the company’s previous results, successfully eliminates cancer because it takes control of the general mechanism of reproduction of cancer cells and restores the body’s balance.
According to its managers, the clinical trial that is now starting is to treat patients with very advanced lung cancer, although in successive phases its application will be extended to other types of cancer, since it prevents cancer progression – metastasis – and induces the self-destruction of the cells by a natural mechanism called «apoptosis», in most known cancers, even in advanced stages. PVT-REMOVE affects only tumor cells, so it has no side effects.
In these Phase II trials, the drug is administered to last-line lung cancer patients to study dose-response curves and evaluate the optimal dose of drug administration.
Vicente Salinas, CEO of PlusVitech, a doctor and physician who has been researching cancer, and especially its relationship with explosive inflammation, for more than ten years, is satisfied with this step. As he explains, «this clinical trial will allow us to demonstrate that PVT-REMOVE is an effective and safe treatment to fight cancer. The results obtained so far show complete remissions in the main types of cancer, such as lung, breast and lymphoma, even in cases that are resistant to currently available treatments. In addition, this treatment can be tailored to each patient through a diagnostic kit managed by a precision medicine tool that includes machine learning systems, for the continuous improvement of our treatments. «I firmly believe that we have found an effective treatment against most of the so-called incurable cancers such as lung cancer,» concludes Dr. Salinas.
For his part, Fran Guillén, CEO of PlusVitech, has pointed out the extraordinary importance of the start of the clinical trial, «this Phase II trial approval in lung cancer patients with no other treatment option is a giant step for PlusVitech, because we will have the opportunity to demonstrate the effectiveness of our treatment even in the most difficult cases and give hope back to patients». «Once the clinical trial is completed, we hope to obtain rapid marketing approval, given that there is no other alternative for them, and to initiate new studies for the other types of cancer in which we are convinced that PVT-REMOVE is also going to be effective». stresses Guillén.
Commitment to the fight against cancer and COVID
PlusVitech has been growing thanks to different supports, such as Impúlsame: an accelerator of companies located in Mairena del Alcor (Seville), and Business Angels such as ILP Abogados with about 10% of the company, as well as many small individual investors who have personally bet on the project during its years of life.
Recently, expert biotech investors such as Santiago Munne and José Horcajadas (Overture) or David Cotán (Pronacera) have joined PlusVitech, as well as renowned business angels such as Sebastián Urbán (Asterion) or Hector García (Geographica) or Delfí Torns (Homu Invest).
Currently, several major international funds are advancing in negotiations to financially support the company’s trials in a new round of financing.
The company continues to advance in the development of «PVT-COVID» a treatment that repositions an oral drug based on an existing drug that, in combination with other previously approved drugs, could save lives by stopping COVID organic lesions such as in the lungs and kidneys, by stopping inflammation and cytokine storm without side effects, and that is not only useful in COVID-19 in its current version, but also works in future mutations, because it does not focus on the virus but on its effects.
